Literature DB >> 22120563

Surgical and endovascular treatment of pediatric spinal arteriovenous malformations.

M Yashar S Kalani1, Azam S Ahmed, Nikolay L Martirosyan, Katharine Cronk, Karam Moon, Felipe C Albuquerque, Cameron G McDougall, Robert F Spetzler, Ruth E Bristol.   

Abstract

OBJECTIVE: Pediatric spinal arteriovenous malformations (AVMs) are rare and complex lesions to treat. There are few reports of the endovascular and microsurgical treatment of these lesions in the pediatric population, and the treatment outcomes of these patients are not well described. The aim of this study was the clinical and radiographic outcomes of spinal AVMs in pediatric patients treated via endovascular and microsurgical modalities.
METHODS: We identified nine children (5 boys, 4 girls; average age 11 years, range 3-17 years) treated for spinal AVMs between 1998 and 2010. Their charts were reviewed.
RESULTS: Spinal AVMs most frequently involved the thoracic spinal cord. Four patients had associated Klippel-Trènaunay-Weber syndrome and one had hereditary hemorrhagic telangiectasia. There were two intramedullary, four conus medullaris, and three mixed extradural-intradural lesions. The most common presenting signs and symptoms were subarachnoid hemorrhage (n = 3) and paraparesis (n = 5). Endovascular intervention was used exclusively in two patients, and combined endovascular and microsurgical intervention was used in four patients. Surgery was the sole treatment in three patients with excellent results. There were two treatment-related complications: one case of subarachnoid hemorrhage and one case of scrotal swelling. The mean follow-up was 28.5 months and the median was 8 months (range, 1-65 months). The mean pretreatment World Health Organization (WHO)/Zubrod score was 2.4 (range, 1-4), and the mean post-treatment score was 1.4 (range, 0-4). One patient (11%) had a recurrence.
CONCLUSIONS: Pediatric spinal AVMs require complex combined microsurgical and endovascular techniques to achieve favorable outcomes.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22120563     DOI: 10.1016/j.wneu.2011.10.036

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Enhanced recovery after surgery in intramedullary and extramedullary spinal cord lesions: perioperative considerations and recommendations.

Authors:  Sauson Soldozy; Parantap Patel; Mazin Elsarrag; Pedro Norat; Daniel M Raper; Jennifer D Sokolowski; Kaan Yağmurlu; Min S Park; Petr Tvrdik; M Yashar S Kalani
Journal:  Spinal Cord       Date:  2019-07-29       Impact factor: 2.772

2.  Intradural spinal cord arteriovenous shunts in the pediatric population: natural history, endovascular management, and follow-up.

Authors:  Arturo Consoli; Stanislas Smajda; Johannes Trenkler; Michael Söderman; Georges Rodesch
Journal:  Childs Nerv Syst       Date:  2019-03-07       Impact factor: 1.475

3.  Pediatric spinal arteriovenous malformations and fistulas: a single institute's experience.

Authors:  Won-Sang Cho; Kyu-Chang Wang; Ji Hoon Phi; Ji Yeoun Lee; Sangjoon Chong; Hyun-Seung Kang; Moon Hee Han; Seung-Ki Kim
Journal:  Childs Nerv Syst       Date:  2016-02-12       Impact factor: 1.475

4.  The role of spinal angiography in the evaluation and treatment of pediatric spinal vascular pathology: a case series and systematic review.

Authors:  Eric Goethe; Melissa A LoPresti; Peter Kan; Sandi K Lam
Journal:  Childs Nerv Syst       Date:  2019-08-14       Impact factor: 1.475

Review 5.  Spinal arteriovenous fistulae in patients with hereditary hemorrhagic telangiectasia: A case report and systematic review of the literature.

Authors:  Waleed Brinjikji; Deena M Nasr; Harry J Cloft; Vivek N Iyer; Giuseppe Lanzino
Journal:  Interv Neuroradiol       Date:  2016-01-27       Impact factor: 1.610

Review 6.  Spinal vascular malformations: treatment strategies and outcome.

Authors:  Bruno C Flores; Daniel R Klinger; Jonathan A White; H Hunt Batjer
Journal:  Neurosurg Rev       Date:  2016-04-13       Impact factor: 3.042

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.